Liver Cancer Trial, Recruiting (NCT06960954)

Liver Cancer Trial, Recruiting NCT06960954 Sponsor: Tanta University Condition: Liver Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT06960954 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Liver Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Adults aged 18 years or older, of any gender.
People who have been diagnosed with hepatocellular carcinoma (a type of liver cancer), with or without spread into nearby blood vessels, confirmed by two imaging scans, or one imaging scan alongside a raised blood protein marker or a tissue sample from the liver.

Who may not be able to join:

People who have previously had treatments directed at the liver tumour (such as ablation, embolisation, or radiation to the liver) or who have had a liver transplant.
People who are currently taking vitamin K supplements, blood-thinning medications that work against vitamin K (such as warfarin), or antibiotics.
People who have a condition where bile is not flowing properly from the liver (confirm with trial site).
People who have reduced kidney function (confirm with trial site).
People who have been diagnosed with another type of cancer.
People who are not willing to take part in the study.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 20 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Rania M Elkafoury, MD, Tropical medicine and infectious diseases Department, Faculty of Medicine, Tanta University

Phone: +201004672358

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06960954

Sponsor: Tanta University

Phase: Not Applicable

Status: Recruiting

Condition: Liver Cancer

Trial contact: +201004672358

More information: https://clinicaltrials.gov/study/NCT06960954

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

Adults aged 18 years or older, of any gender.
People who have been diagnosed with hepatocellular carcinoma (a type of liver cancer), with or without spread into nearby blood vessels, confirmed by two imaging scans, or one imaging scan alongside a raised blood protein marker or a tissue sample from the liver.

Who may not be able to join:

People who have previously had treatments directed at the liver tumour (such as ablation, embolisation, or radiation to the liver) or who have had a liver transplant.
People who are currently taking vitamin K supplements, blood-thinning medications that work against vitamin K (such as warfarin), or antibiotics.
People who have a condition where bile is not flowing properly from the liver (confirm with trial site).
People who have reduced kidney function (confirm with trial site).
People who have been diagnosed with another type of cancer.
People who are not willing to take part in the study.

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 20 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Tanta University

Registry

ClinicalTrials.gov

Start date

15 January 2025

Est. completion

15 December 2025

Where this trial is recruiting

🇪🇬 Egypt

Primary endpoints

PIVKA-II serum level for prediction of PVTT in HCC patients.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov